SequelSEC

BIOFORCE NANOSCIENCES HOLDINGS, INC. BFNH

Laboratory Analytical Instruments · CIK 0001310488 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$17.78K
Fiscal year ended 2019-12-31
Operating income
-$46.54K
Fiscal year ended 2019-12-31
Free cash flow
Unavailable
Fiscal year ended 2019-12-31

BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) reported revenue of $17.78K and net income of -$46.54K for the fiscal year ended 2019-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from BIOFORCE NANOSCIENCES HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

BIOFORCE NANOSCIENCES HOLDINGS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312018-12-312017-12-31
Revenue$17.78K$16.31K$4.50K
Cost of revenue$13.42K$11.64K$3.24K
Gross profit$4.36K$4.66K$1.26K
Operating income-$46.54K-$66.74K-$31.26K
Net income-$46.54K-$67.74K-$31.26K
Research & developmentUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailable
Pretax income-$46.54K-$67.74K-$31.26K
Income tax expense$0$0Unavailable
Diluted EPSUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$50.90K$71.40K$32.52K
Selling & marketingUnavailableUnavailableUnavailable

Balance

BIOFORCE NANOSCIENCES HOLDINGS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312018-12-312017-12-31
Cash & equivalents$52.90K$29.39K$14.32K
Total assets$58.90K$35.13K$20.91K
Current assets$58.90K$35.13K$20.91K
Total liabilities$11.59K$5.32K$12.71K
Current liabilities$11.59K$5.32K$12.71K
Total equity incl. NCI$47.31K$29.80K$8.20K
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailable$5.74K$4.50K
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailable

Cash flow

BIOFORCE NANOSCIENCES HOLDINGS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312018-12-312017-12-31
Operating cash flow-$24.38K-$62.47K-$25.90K
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailable
Financing cash flow$47.89KUnavailableUnavailable
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

BIOFORCE NANOSCIENCES HOLDINGS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312018-12-312017-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross margin24.5%28.6%27.9%
Operating marginUnavailable-409.2%-694.7%
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio5.08x6.60x1.65x
Revenue YoY growth9.0%262.4%Unavailable
Net margin-261.8%-415.3%-694.7%
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BFNH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-19View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

A ASTC AVTR BIO BNGO BRKR CTKB EYPT HBIO ILMN LCTC MASS

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.